|
|
|
| Analysis on the medicine law of traditional Chinese medicine compound prescriptions in the treatment of diabetic nephropathy based on national patent database#br# |
| ZHOU Chunmei1 XIAO Yang2 LU Bo2 YUAN Qiuzhen1 QI Haiyan2 HANG Cheng2 CHENG Luping2 WANG Gaolei2 |
1.Department of Pharmacy, Shaanxi Provincial Hospital of Chinese Medicine, Shaanxi Province, Xi’an 710003, China;
2.the Second Department of Endocrinology, Shaanxi Provincial Hospital of Chinese Medicine, Shaanxi Province, Xi’an 710003, China |
|
|
|
Abstract Objective To study the medicine law of patent traditional Chinese medicine compound prescriptions in the treatment of diabetic nephropathy in China in the past 20 years through data mining techniques. Methods Traditional Chinese medicine compound prescriptions in the treatment of diabetic nephropathy in CNKI patent database from January 1, 2000 to December 31, 2020 were searched, and traditional Chinese medicine compound prescriptions met the research requirements were recorded into traditional Chinese medicine inheritance support system V2.5. The frequency of drug usage, flavour, meridian tropism and prescription laws were analyzed by using the methods of frequency statistics, association rule analysis, and so on. Results A total of 214 patent prescriptions were selected, involving 374 kinds of traditional Chinese medicine, and the top five medicines in the rank of use frequency were Radix Astragali seu Hedysari, Radix Salviae Miltiorrhizae, Rhizoma Dioscoreae, Radix et Rhizoma Rhei, Fructus Corni; the top three of drugs classifies were tonifying deficiency drugs (tonifying qi drugs were mainly used), promoting blood circulation for removing blood stasis drugs, promoting diuresis and permeating dampness drugs; the top three of four nature of drugs were warm, cold and flat; the top three of five flavours were sweet, bitter and pungent; and the top three of channel tropism were liver meridian, spleen meridian and kidney meridian. According to association rules, seven pairs of commonly used couplet medicines were analyzed, and four new prescriptions were analyzed by entropy clustering method. Conclusion Traditonal Chinese medicine patent compound prescriptions for treating diabetic nephropathy are mainly tonifying deficiency and eliminating pathogen, tonifying deficiency mainly involves tonifying qi, tonifying liver and kidney, eliminating pathogen mainly involves promoting blood circulation, promoting dampness and clearing heat, which can be used as a clinical reference.
|
|
|
|
|
|
[1] Guo K，Zhang L，Zhao F，et al. Prevalence of chronic kidney disease and associated factors in Chinese individuals with type 2 diabetes：cross sectional study [J]. J Diabetes Complications，2016，30（5）：803-810.
[2] 李菲，王秋虹，魏军平.中医药治疗糖尿病肾病的临床研究进展[J].医学综述，2020，26（17）：3471-3475.
[3] 王志刚，贺云龙，田侃.专利转化视角下我国中药专利审查方式的再思考[J].中国卫生事业管理，2014，31（12）：924-928.
[4] 高学敏.中药学[M].北京：中国中医药出版社，2014.
[5] 国家药典委员会.中华人民共和国药典[S].一部.北京：中国医药科技出版社，2020.
[6] Barrett EJ，Liu Z，Khamaisi M，et al. Diabetic microvascular disease：an endocrine society scientific statement [J]. J Clin Endocrinol Metab，2017，102（12）：4343-4410.
[7] 祝菁菁，范文君，黄韻宇，等.我国2型糖尿病及糖尿病肾病的经济负担现状[J].中国卫生经济，2013，32（4）：32-34.
[8] Zhong Y，Lee K，Deng Y，et al. Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes [J]. Nat Commun，2019，10（1）：4523.
[9] Perkovic V，Jardine MJ，Neal B，et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [J]. N Engl J Med，2019，380（24）：2295-2306.
[10] Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors [J]. Diabetes Obes Metab，2019，21（Suppl 2）：34-42.
[11] 张海力，李靖，王世长，等.中医药治疗糖尿病肾病最新进展[J].中国中西医结合肾病杂志，2019，20（9）：831-833.
[12] 刘蓬蓬，单国顺，张凡，等.UPLC-MS比较有机酸定向炮制黄芪中12种活性成分的含量[J].中国中药杂志，2020，45（1）：113-118.
[13] Mao Q，Chen C，Liang H，et al. Astragaloside Ⅳ inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-β1/Smad/miR-192 signaling pathway [J]. Exp Ther Med，2019，18（4）：3053-3061.
[14] Ju Y，Su Y，Chen Q，et al. Protective effects of Astragaloside Ⅳ on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats [J]. Biomed Pharmacother，2019，109：84-92.
[15] 郭晓玲，康丽霞，任美芳，等.黄芪多糖对糖尿病肾病肾小管上皮细胞凋亡、转分化及ROS含量的影响研究[J].中国免疫学杂志，2018，34（3）：388-392.
[16] Lei X，Zhang BD，Ren JG，et al. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway [J]. Life Sci，2018，206：77-83.
[17] Zhang R，Qin X，Zhang T，et al. Astragalus Polysaccharide Improves Insulin Sensitivity via AMPK Activation in 3T3-L1 Adipocytes [J]. Molecules，2018，23（10）：2711.
[18] 宋经元，罗红梅，李春芳，等.丹参药用模式植物研究探讨[J].药学学报，2013，48（7）：1099-1106.
[19] 王钦汶，戴新新，项想，等.丹酚酸和丹参酮干预糖尿病肾病的分子机制研究进展[J].药学学报，2019，54（8）：1356-1363.
[20] 陈梦雨，刘伟，侴桂新，等.山药化学成分与药理活性研究进展[J].中医药学报，2020，48（2）：62-66.
[21] 高子涵，李瑞芳，吕行直，等.山药多糖对糖尿病肾病小鼠肾功能和醛糖还原酶通路的影响[J].中药材，2019， 42（3）：643-646.
[22] 郝洁，梁艳，张瑞，等.大黄素改善糖脂代谢异常、糖尿病周围神经病变及糖尿病肾病的作用机制研究进展[J].中药药理与临床，2020，36（3）：265-272.
[23] 戴国英.基于肾系膜细胞损伤研究生地、山茱萸特征成分对糖尿病肾病的保护作用及机制[D].南京：南京中医药大学，2017：1-57.
[24] 江旭锋，曾庆春，黄岑汉，等.糖尿病肾病中医病因病机探要[J].河南中医，2016，36（5）：924-926.
[25] 赵婷婷，张浩军，严美花，等.糖肾方改善糖脂代谢紊乱“肝肾同治”机制研究[J].世界科学技术-中医药现代化，2018，20（8）：1443-1447.
[26] 于淼，王秀阁，李瑞恩，等.浅谈糖尿病肾病中医病机[J].新中医，2020，52（18）：186-189. |
|
|
|
